Posts by: Alice Melão

News

Autolus has initiated two Phase 1/2 trials to test AUTO3, a new CAR T-cell therapy that targets two cancer proteins instead of one. The trials, AMELIA and ALEXANDER, will be ... Read more

September 20, 2017September 20, 2017

Biosimilar GP2013 Is Equivalent to Rituxan as Lymphoma Therapy, Phase 3 Trial Shows

News

Lymphoma patients’ response to Sandoz’s biosimilar therapy GP2013 was similar to their response to the treatment from which it is derived, Genentech’s Rituxan (rituximab), a Phase 3 clinical trial indicates. Sandoz presented ... Read more

September 12, 2017

Transplant Recipients Account for 3% of non-Hodgkin Lymphoma Cases in Children, Study Finds

News

Nearly three out of every 100 cases of non-Hodgkin lymphoma in American children and adolescents occurs in those who received an organ transplant, a study reports. The research showed that the ... Read more

September 11, 2017September 11, 2017

Advisory Agency Decision Will Make Lymphoma Therapy Adcetris More Accessible in UK

News

Britain’s national health service advisory agency has made a decision that will make Adcetris (brentuximab vedotin) more accessible as a treatment for an aggressive type of lymphoma. The National Institute for Health and ... Read more

August 29, 2017August 29, 2017

Gilead to Become Cell Therapy Leader Once $11.9B Acquisition of Kite Pharma Closes

News

Just a few months before the U.S. Food and Drug Administration is expected to reach a decision on Kite Pharma‘s application seeking approval for its therapy axicabtagene ciloleucel (axi-cel) for the treatment ... Read more

August 28, 2017August 28, 2017

FDA Grants Breakthrough Therapy Status to Lymphoma Treatment Poteligeo

News

The U.S. Food and Drug Administration has granted breakthrough therapy designation to Poteligeo (mogamulizumab) as a treatment for mycosis fungoides and sézary syndrome, the most common subtypes of cutaneous T-cell lymphoma, ... Read more

August 25, 2017August 25, 2017

Phase 3 Trial Underway to Assess Gilteritinib as Maintenance Therapy in Certain AML Patients

News

The first participant has begun treatment in a new Phase 3 clinical trial assessing Astellas Pharma‘s gilteritinib as a maintenance therapy for certain acute myeloid leukemia (AML) patients who are in remission ... Read more

August 3, 2017

Kite Seeks EU Approval for CAR T-Cell Therapy in 3 Lymphoma Subtypes

News

Kite Pharma submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) requesting the approval of its CAR T-cell therapy, axicabtagene ciloleucel, as treatment for patients with certain ... Read more

August 2, 2017

FDA Grants Breakthrough Therapy Designation to Acalabrutinib for Mantle Cell Lymphoma

News

The U.S. Food and Drug Administration has granted breakthrough therapy designation to acalabrutinib as a treatment for patients with mantle cell lymphoma who have received at least one other therapy. This designation is ... Read more

July 31, 2017

Imbruvica Improves Quality of Life of Relapsed or Refractory Mantle Cell Lymphoma Patients, Trial Shows

News

Patients with relapsed or refractory mantle cell lymphoma have a better quality of life with Imbruvica (ibrutinib) than Torisel (temsirolimus), a Phase 3 clinical trial suggests. The finding was published in the journal Leukemia ... Read more